Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lipoproteins – e.g. – egg yolk proteins – cylomicrons – etc.
Reexamination Certificate
2007-03-20
2007-03-20
Gupta, Anish (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lipoproteins, e.g., egg yolk proteins, cylomicrons, etc.
C530S421000, C530S422000, C530S424000, C435S069100
Reexamination Certificate
active
10863456
ABSTRACT:
The present invention relates to a process for purifying a hydrophobic or amphiphilic compound, by first mixing a starting material containing the hydrophobic or amphiphilic compound with a first polymeric material, water and at least one of a second polymeric material and a surfactant, wherein the first polymeric material and the second polymeric material and/or surfactant are immiscible in the resulting primary aqueous solution. The process further comprises maintaining the primary aqueous solution for a period of time sufficient for essentially separating the phases formed, and then removing the phase containing the main portion of the hydrophobic or amphiphilic compound and the second polymeric material and/or surfactant. The second polymeric material and/or surfactant are separated from the hydrophobic or amphiphilic compound, and subsequently recycled to the initial mixing step. The present invention further relates to a composition for use in purification of apolipoprotein A (ApoA) or apolipoprotein E (ApoE), said composition comprising a first polymeric material and a surfactant, said first polymeric material and surfactant being immiscible in the primary aqueous solution obtained after mixing with water. ApoA or ApoE produced by the inventive process can be used for the manufacture of a medicament in the treatment of atherosclerosis and cardiovascular diseases, sepsis or peripheral atherosclerosis as well as in a method for treatment of atherosclerosis and cardiovascular diseases, sepsis or peripheral atherosclerosis when administered in a therapeutically effective amount.
REFERENCES:
patent: 4740304 (1988-04-01), Tjerneld et al.
patent: 5059528 (1991-10-01), Bollen et al.
patent: 5721114 (1998-02-01), Abrahamsen et al.
patent: 5834596 (1998-11-01), Ageland et al.
patent: 5876968 (1999-03-01), Sirtori et al.
patent: 6107467 (2000-08-01), Ageland et al.
patent: 6767994 (2004-07-01), Ageland et al.
patent: 0262651 (1988-04-01), None
patent: 0308336 (1989-03-01), None
patent: 0574050 (1993-12-01), None
patent: 61-96998 (1986-05-01), None
patent: 01-95798 (1989-04-01), None
patent: 06-228319 (1994-08-01), None
patent: WO 8803166 (1988-05-01), None
patent: WO 9012879 (1990-11-01), None
patent: WO 9312143 (1993-06-01), None
patent: WO 9325581 (1993-12-01), None
patent: WO 9413819 (1994-06-01), None
patent: WO 9623061 (1996-08-01), None
patent: WO 9627608 (1996-09-01), None
Eisenberg et al (1982),Nature, vol. 229, pp. 371-374.
Johansson (1974),Acta Chemica Scandinavica., vol. 28, pp. 873-882.
Walter et al (1994),Methods in Enzymology, vol. 228, pp. 28-42 and 627-640.
Harris et al (1991),Bioseparation, vol. 2, pp. 237-246.
Alred et al, (1993),J. Chromatography., vol. 628, pp. 205-214.
Alred et al (1992),Bioseparation, vol. 2, pp. 363-373.
Alred et al (1994),J. Chromatography A, vol. 659, pp. 289-298.
Bradford (1976),Analytical Biochemistry, vol. 72, pp. 248-254.
Berggren et al (1995),J. Chromatography A, vol. 718, pp. 67-79.
Weisgraber et al (1980),J. Clin. Invest., vol. 66, pp. 901-907.
Keshavarz et al (1979),Biochimica et Biophysica Acta, vol. 576, pp. 269-279.
Nguyen et al (1988),Appl. Microbiol Biotechnology, vol. 27, pp. 341-346.
Modlin et al (1974),J. of Chromatography A. vol. 668, pp. 229-236.
Galaev et al (1993),Enzyme Microb. Technol, vol. 15, pp. 354-366.
Deeb et al (1991),J. Biological Chemistry, vol. 266, No. 21, pp. 13654-13660.
Takada et al, (1991),J. Lipid Research., vol. 32, pp. 1275-1280.
Matsunaga et al (1991),Proc. Natl. Acad. Sci. USA. vol. 88, pp. 2793-2797.
Sirtori et al (1993), Human Apolipoprotein Mutants III,NATO ASI Series,. vol. II 73, pp. 81-96.
Brewer et al (1978),Biochemical and Biophysical Research Communications, vol. 80, No. 3, pp. 623-630.
Robb et al (1995),J. Chem. Soc. Faraday Trans., vol. 91, pp. 3901-3906.
Wan et al (1974),J. Pharmaceutical Sciences, vol. 2, pp. 136-137.
Garg et al (1994),Biotechnol. Appl. Biochem., vol. 20, pp. 199-215.
Wiegel et al (1994),J. Chromatography B, vol. 661, pp 159-164.
Calabresi et al (1994), J. of Biol. Chem., vol. 269, No. 23, pp. 32168-32174.
Soma et al (1995),Circ. Res., vol. 76, No. 3, pp. 405-411.
Fukushima et al (1981),Proceedings of the Natl. Acad. of Sci. of the USA, vol. 78, No. 5, pp. 2732-2736 (abstract only).
Braddock et al Chem. Abstract No. 116:78749 (1992).
Ageland Hans
Nyström Lena
Persson Josefine
Tjerneld Folke
Ashbrook Charles W.
Eck Steven W.
Gupta Anish
Pharmacia & UpJohn AB
LandOfFree
Process for purifying a compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for purifying a compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for purifying a compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3756454